NeuroSense Therapeutics Ltd. (NRSNW)

IL — Healthcare Sector
Peers: NRSN  KTTAW  GOVXW  NLSPW  CINGW 

Automate Your Wheel Strategy on NRSNW

With Tiblio's Option Bot, you can configure your own wheel strategy including NRSNW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NRSNW
  • Rev/Share 0.0
  • Book/Share 0.1112
  • PB 13.8492
  • Debt/Equity 0.0283
  • CurrentRatio 2.2098
  • ROIC -3.7124

 

  • MktCap 36942549.0
  • FreeCF/Share 0.0
  • PFCF 0.0
  • PE -3.5037
  • Debt/Assets 0.016
  • DivYield 0
  • ROE 4.5728

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About NeuroSense Therapeutics Ltd. (NRSNW)

  • IPO Date
  • Website https://www.neurosense-tx.com
  • Industry Biotechnology
  • CEO Mr. Alon Ben-Noon
  • Employees 17
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.